You are here

P&T News

September 18

Single-dose oral therapy treats leading gynecological infection
Injection is also approved for GEP-NETs

September 15

Approval based on totality of evidence from global development program showing Mvasi is highly similar to Genentech’s Avastin
Panel believes GSK’s Shingrix represents an improvement over Merck’s Zostavax
In a clinical trial, the prescription-only adjunct treatment significantly increased patient adherence to abstinence

September 14

Options limited for patients, whose disease often returns
New study puts price of 10 cancer drugs at $648 million each
Vaccine protects against two A strain and two B strain viruses
Sotagliflozin may improve glucose control without increasing weight or hypoglycemia
Amicus won’t pursue wound-healing agent SD-101 for epidermolysis bullosa

September 12

New study examines impact of Medicaid changes
Dual testing no longer needed; screening interval can be up to 5 years
Company aims to prevent Restasis challenges at U.S. patent office
Three sub-analyses parse results of EMPA-REG OUTCOME trial
Less expensive corticosteroids could treat the same problems

September 11

Studies at ESMO may lead to wider use of medications
ACR20 responses at two doses reach 65% and 56% at 12 weeks
Johnson & Johnson unit will focus on hepatitis B instead

Pages